Director share purchases

RNS Number : 5310E

Arix Bioscience Plc

09 May 2017

 

Director share purchases

LONDON, 09 May 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, announces that several key members of its leadership team have purchased shares in the Company.

Joe Anderson, Chief Executive Officer of Arix Bioscience, purchased 21,532 ordinary shares in the Company at a price of 202.39p per Ordinary Share.

Jon Peacock, Chairman of Arix Bioscience, purchased 11,484 ordinary shares in the Company at a price of 202.39p per Ordinary Share.

James Rawlingson, Chief Financial Officer of Arix Bioscience, purchased 11,484 ordinary shares in the Company at a price of 202.39p per Ordinary Share. 

PDMR Dealing Notifications

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Joseph Anderson
2	Reason for the notification
a)	Position / status	Chief Executive Officer
b)	Initial notification / Amendment	Initial Notification
3	Details of issuer
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of Arix Bioscience plc
	Identification code	GB00BD045071
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		202.39 pence	21,532
d)	Aggregated information	Aggregated price	Aggregated volume
		N/A (single transaction)	N/A (single transaction)
e)	Date of the transaction	08 May 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jonathan Peacock
2	Reason for the notification
a)	Position / status	Chairman
b)	Initial notification / Amendment	Initial Notification
3	Details of issuer
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of Arix Bioscience plc
	Identification code	GB00BD045071
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		202.39 pence	11,484
d)	Aggregated information	Aggregated price	Aggregated volume
		N/A (single transaction)	N/A (single transaction)
e)	Date of the transaction	08 May 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	James Hedley Rawlingson
2	Reason for the notification
a)	Position / status	Chief Financial Officer
b)	Initial notification / Amendment	Initial Notification
3	Details of issuer
a)	Name	Arix Bioscience plc
b)	LEI	213800OVT3AHQCXNIX43
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of Arix Bioscience plc
	Identification code	GB00BD045071
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		202.39 pence	11,484
d)	Aggregated information	Aggregated price	Aggregated volume
		N/A (single transaction)	N/A (single transaction)
e)	Date of the transaction	08 May 2017
f)	Place of the transaction	London Stock Exchange (XLON)

For more information, please contact:

Arix Bioscience plc

Joe Anderson, CEO

[phone]

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

 

END

 

 

DSHSSWESAFWSEII